Barclays Keeps a Hold Rating on AbbVie

By Jason Carr

In a report released today, Geoff Meacham from Barclays maintained a Hold rating on AbbVie (NYSE: ABBV), with a price target of $90. The company’s shares opened today at $91.41, close to its 52-week high of $92.61.

According to, Meacham is a 4-star analyst with an average return of 8.4% and a 57.0% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Achillion Pharmaceuticals.

Currently, the analyst consensus on AbbVie is Moderate Buy and the average price target is $95.64, representing a 4.6% upside.

In a report issued on September 28, BMO Capital also assigned a Hold rating to the stock with a $66 price target.

AbbVie’s market cap is currently $145.7B and has a P/E ratio of 22.46. The company has a book value ratio of 24.2466.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.